

Study of Inorganic Iodine level in prevalent Haemodialysis Patients

Thesis

*Submitted for partial fulfillment of Master Degree in
Internal Medicine*

By

Mohamed Atef Abd El-Mohsen Soliman

M.B, B.Ch,
Faculty of medicine, Ain Shams University

Supervised by

Prof. Mohamed Aly Ibrahim

Professor of Internal Medicine and Nephrology
Faculty of medicine, Ain Shams University

Dr. Mohamed Saeed Hassan

Lecturer of Internal Medicine and Nephrology
Faculty of medicine, Ain Shams University

Dr. Ramy Mohamed Mahmoud

Lecturer of clinical pathology
Faculty of medicine, Ain Shams University

**Faculty of medicine
Ain Shams University**

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

First and foremost thanks to ALLAH, the Most Merciful.

*I wish to express my deep appreciation and sincere gratitude to **Prof Dr. Mohamed Aly Ibrahim**, Professor of Internal Medicine and nephrology, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience, advices and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his direct supervision.*

*I wish to express my great thanks and gratitude to **Dr. Mohamed Saeed Hassan** lecturer of Internal Medicine and nephrology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

*I wish to express my great thanks and gratitude to **Dr. Ramy Mohamed Mahmoud** Lecturer of Clinical Pathology, Ain Shams University, for his kind supervision, indispensable advice and great help in this work.*

Last and not least, I want to thank all my family, my colleagues,, for their valuable help and support.

Finally I would present all my appreciations to my patients without them, this work could not have been completed.

Contents

Subjects	Page
• List of Abbreviations	I
• List of table	III
• List of Figures	V
• Introduction	1
• Aim of the Work.....	3
• Review of literature:	
Chapter (1): Thyroid disorders in hemodialysis patients	4
Chapter (2): Iodine, Iodine metabolism and Iodine disorders in hemodialysis patients	26
Chapter (3): Drug induced thyroid disorders and Iodine related drugs	42
• Patients And Methods.....	63
• Results.....	68
• Discussion.....	85
• Summary	95
• Conclusion	99
• Recommendation	100
• References	101
• Arabic Summary	-

List of Abbreviations

ACE-I	Angiotensin converting enzyme Inhibitors
AED	Antiepileptic drugs
AIDS	Acquired immune deficiency syndrome
AIH	Amiodarone-induced hypothyroidism
AIT	Amiodarone-induced thyrotoxicosis
BMI	Body mass index
CAPD	Continuous ambulatory peritoneal dialysis
CCBs	Calcuim channel blockers
CHD	Coronary heart disease
CHF	Congestive heart failure
CKD	Chronic kidney disease
CVD	Coronary vascular disease
DIT	Diiodotyrosine
ESA	Erythropoiesis stimulating agents
ECF	Extracellular fluid
ESRD	End stage renal disease
FFA	Free fatty acids
Free T3	Triiodothyronine
Free T4	Free thyroxine
GFR	Glomerular filtration rate
HAART	Highly active antiretroviral therapy
HCV	Hepatitis C virus
HD	Hemodialysis
HIV	Human immune deficiency virus
hs-CRP	Highly sensitive C-reactive protein
IDD	Iodine deficiency disorder
IGF-1	Insulin growth factor-1
IL-1	Interleukin-1
INFα	Interferon alpha
LDL	Low density lipoprotein
MIT	Monoiodotyrosine
mRNA	Messenger ribonucleic acid
NIS	Sodium iodide symporter
NSAIDs	Nonsteroidal anti-inflammatory drugs
NTI	Non thyroidal illness
PD	Peritoneal dialysis
rT3	Reverse T3
TBG	Thyroid binding globulin
TG	Thyroglobulin
TFT	Thyroid function tests

List of Abbreviations

TNF	Tumor necrosis factor
TRH	Thyrotropin releasing hormone
TSH	Thyroid stimulating hormone
VPA	Valproate

List of Table

Tab. No.	Subject	Page
Table (1)	shows the descriptive data of the study population	68
Table (2)	showing Antihypertensive medications of cases	69
Table (3)	shows laboratory data of the study population.	70
Table (4)	shows comparison between patients and controls as regards Free T4, TSH and Free T3	71
Table (5)	shows ultrasound findings of cases and controls	71
Table (6)	show the comparison between median iodine levels in patients and controls.	72
Table (7)	shows correlation between Iodine level and age and duration of HD in all patients.	73
Table (8)	shows that there is a highly statistically significant negative correlation between iodine level & (Free T4 & TSH) (P=0. 005)	73
Table (9)	shows comparison between patients with normal Iodine and patients with high Iodine as regard demographic data	76
Table (10)	Gender distribution in two groups.	76
Table (11)	shows comparison between patients with normal Iodine and patients with high Iodine as regard laboratory data.	77
Table (12)	shows that group with high Iodine level has <i>significant lower levels of FT4 in comparison to group with normal Iodine level control (p=0. 017), with no significant difference in TSH or FT3.</i>	78
Table (13)	shows that there was no significant difference between groups as regards classification according to thyroid functions where low T3 syndrome was defined as normal TSH and FT4 levels with low T3 and subclinical hypothyroidism is high TSH with normal T3 and T4 levels.	97
Table (14)	shows that patients with high iodine have higher incidence of thyroid nodules than patients with normal iodine, with no significant difference in other parameters.	80

List of Table

<i>Tab. No.</i>	<i>Subject</i>	<i>Page</i>
Table (15)	shows that there is no a statistically significant correlation between iodine level & age and duration of HD in patients with High iodine level.	80
Table (16)	shows that there is a statistically significant negative correlation between iodine level & TSH (P<0. 05) in patients with high iodine level.	81
Table (17)	shows that there is a statistically insignificant correlation between iodine level & age, duration of HD in patients with Normal iodine level.	81
Table (18)	shows that there is a statistically insignificant correlation between iodine level Free T4, TSH, and Free T3 in patients with Normal iodine level.	81
Table (19)	shows that only Free T4 is an independent predictor of iodine level in all cases (P=0. 018).	82
Table (20)	shows that none of the studied variables is an independent predictor of iodine level in cases with High iodine.	82
Table (21)	shows that none of the studied variables is an independent predictor of iodine level in cases with normal iodine	83
Table (22)	shows the level of iodine in potable water and in dialysate water pre and post dialyzer and it reflects that iodine level increases in post dialyzer dialysate.	83
Table (23)	shows the difference between serum iodine level pre and post dialysis and it showed that serum level of iodine may increase after dialysis session.	84

List of Figures

Fig. No.	Subject	Page
Fig. (1)	Effects of chronic kidney disease on thyroid gland and thyroid hormones	8
Fig. (2)	Effect of ESRD on T3 and T4 levels (pathophysiologic mechanisms)	10
Fig. (3)	The renal manifestations of thyroid diseases	23
Fig. (4)	Sources of iodine	28
Fig. (5)	Iodine metabolism	33
Fig. (6)	Causes of iodine deficiency disorders	40
Fig. (7)	Manifestations of iodine deficiency disorders	41
Fig. (8)	Drug interaction between kidney and thyroid	43
Fig. (9)	Pathophysiologic effects of amiodarone on thyroid	48
Fig. (10)	Effect of amiodarone on thyroid profile	49
Fig. (11)	Treatment protocol for AIT and AIH	50
Results		
Fig. (1)	Antihypertensive medications of cases.	69
Fig. (2)	show the comparison between median iodine levels in patients and controls.	72
Fig. (3)	Correlation between Iodine and Free T3	74
Fig. (4)	Correlation between Iodine and Free T4	74
Fig. (5)	Correlation between Iodine and Free TSH.	75
Fig. (6)	Gender distribution two groups.	77
Fig. (7)	Comparison between median levels of thyroid hormones in two groups.	78
Fig. (8)	Interpretation of thyroid profile in two groups	79

Introduction

The kidney normally plays an important role in the metabolism, degradation, and excretion of several thyroid hormones. It is not surprising therefore that impairment in kidney function leads to disturbed thyroid physiology, all levels of the hypothalamic-pituitary-thyroid axis may be involved, including alteration in hormone production, distribution, and excretion, epidemiologic data suggest that predialysis patients with chronic kidney disease have an increased risk of hypothyroidism; many cases are subclinical (*Kumar et al., 2015*).

Epidemiologic studies show that there is a substantially higher prevalence of thyroid functional disease, and in particular hypothyroidism, in ESRD patients compared with the general population (*Rhee et al., 2014*).

These changes seen in patients with ESRD are due to alterations in the peripheral 5'-monodeiodination of T4, reduced levels of plasma proteins that bind T4, the presence of inhibitors of T4 binding to plasma proteins, metabolic acidosis, and effects of medications. Heparin, among other drugs, inhibit T4 binding to plasma proteins and may transiently elevate free T4 levels (*Mariani & Berns, 2012*).

The kidney plays a role in clearance of iodine, TSH, and thyrotropin-releasing hormone. However, most patients with CKD are euthyroid, with normal TSH and free T4 levels. Patients with uremia may have changes in thyroid

function tests consistent with the euthyroid sick syndrome (*Mariani & Berns, 2012*).

The decrease of excretion of urinary iodine in CRF increases serum inorganic iodine level and iodine content of the thyroid, which consequently enlarges the gland (*Kutlay et al., 2005*). .

Aim of the work

To assess the level of inorganic iodine in prevalent haemodialysis patients and to correlate the findings with thyroid functions tests and thyroid ultrasound.

Thyroid disorders in hemodialysis patients

Thyroid gland is one of the largest endocrine glands in the body. It is found in the anterior neck. The thyroid gland controls rate of use of energy sources, protein synthesis, and controls the body's sensitivity to other hormones. It participates in these processes by producing thyroid hormones, the principal ones are thyroxine (T_4) and triiodothyronine (T_3), which is more active. These hormones regulate the growth and rate of function of many other systems in the body. T_3 and T_4 are synthesized from iodine and tyrosine. The thyroid also produces calcitonin, which plays a role in calcium homeostasis (*Boulpaep et al., 2009*).

Thyroid hormones production is controlled by a complex mechanism of positive and negative regulation. Hypothalamic TSH-releasing hormone (TRH) stimulates TSH secretion from the anterior pituitary. TSH then initiates thyroid hormones synthesis and release from the thyroid gland. The synthesis of TRH and TSH subunit genes is inhibited at the transcriptional level by thyroid hormones, which also inhibits post-translational modification and release of TSH. Although opposing TRH and thyroid hormones inputs regulate the hypothalamic-pituitary-thyroid axis, Thyroid hormones negative feedback at the pituitary was thought to be the primary regulator of serum TSH levels (*Chiamolera & Wondisford, 2009*).

The interplay between thyroid and the kidney in each other's functions is known for many years. Thyroid dysfunction affects renal physiology and development. Thyroid hormones affect kidney function by mediating effects on cardiac output and renal blood flow, contributing to changes in GFR. Thyroid hormones also have direct effects on the kidney by influencing GFR, tubular secretory and reabsorptive functions, and electrolyte homeostasis (*Basu & Mohapatra, 2012*).

On the other side the kidney plays an important role in the metabolism, degradation and excretion of thyroid hormones. CKD affects thyroid function in many ways, including low circulating thyroid hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland (*Malyszko et al., 2006*).

Even disorders of the thyroid and kidney may co-exist with common etiological factors. In addition, treatment strategies of one disease may affect those of the other organ (*Basu & Mohapatra, 2012*)

Thyroid disorders in hemodialysis patients:

Despite solid epidemiologic evidence, the nature of this relation is not fully understood due to complexities in thyroid function evaluation in the presence of uremia and other factors such as reduced thyroid hormone signaling at

the level of the nephron and systemic hemodynamic disorders which are consequences of hypothyroidism on the kidney (*Mariani & Berns, 2012*).

It is not surprising that impairment in kidney function leads to impaired thyroid physiology, all levels of the hypothalamic-pituitary-thyroid axis may be involved, including alteration in hormone production, distribution, and excretion (*Chonchol et al., 2008*).

The prevalence of subclinical hypothyroidism in general population is 9.6%, with higher incidence in women and it is found to be linked to an increased frequency of high titer of anti-thyroid antibodies, while the prevalence increases to 17.9% in patients with GFR <60 mL/min/1.73m² (*Bell et al., 2007*).

As a consequence, the interest in the recent years was to get benefit from the growing evidence that suggests that overt or subclinical hypothyroidism could represent a therapeutic target to improve quality of life and to decrease mortality and morbidity patients with chronic renal failure (*Shin et al., 2013*).

Several clinical manifestations of both hypothyroidism and chronic renal failure are alike. Some manifestations of hypothyroidism such as pallor, hypothermia and asthenia may also occur in uremia and the exclusion of diagnosis of hypothyroidism on clinical grounds may be extremely difficult that's why all chronic renal failure patients with